The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NTHI | N/A | N/A | N/A | -40% |
| S&P | +12.33% | +84.73% | +13.06% | +17% |
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Los Angeles, CA.
No news articles found for NeOnc Technologies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $173.96M | 0.0% |
| Market Cap / Employee | $43.49M | 0.0% |
| Employees | 4 | 33.3% |
| Net Income | -$8.62M | -294.4% |
| EBITDA | -$6.93M | -215.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.51M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.31M | 0.0% |
| Short Term Debt | $4.77M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | 161.31% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.81M | 0.0% |
| Operating Free Cash Flow | -$5.81M | 0.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | -24.09 | -7.06 | -14.62 | - | |
| Price to Sales | 1132.28 | 2907.86 | - | ||
| Price to Tangible Book Value | -24.09 | -7.06 | -14.62 | - | |
| Enterprise Value to EBITDA | -6.30 | -11.95 | -25.67 | - | |
| Total Debt | $0.02M | $0.00M | $0.40M | $5.08M | -23.10% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
